SEC Form 4 · accession 0000899243-17-000893
PROVECTUS BIOPHARMACEUTICALS, INC. · PVCT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter R Culpepper
Other
Period of report
Dec 28, 2016
Accepted (ET)
Jan 9, 2017 · 8:55 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000315545
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | holding | — | — | — | 1,411,829 | D | ||
| Common Stock | holding | — | — | — | 296,503 | I | By 401(k) plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Share Option (Right to buy) | $1.00 | holding | — | — | — | Jul 22, 2010 | Jul 22, 2020 | Common Stock | 550,000 | 550,000 | D |
| Share Option (Right to buy) | $0.93 | holding | — | — | — | Sep 6, 2011 | Sep 6, 2021 | Common Stock | 550,000 | 550,000 | D |
| Share Option (Right to buy) | $0.75 | holding | — | — | — | Dec 9, 2015 | Dec 9, 2025 | Common Stock | 400,000 | 400,000 | D |
| Warrant (Right to buy) | $0.85 | holding | — | — | — | Mar 29, 2016 | Jun 19, 2020 | Common Stock | 266,666 | 266,666 | D |
Remarks
On December 28, 2016, the reporting person, Peter Culpepper, was terminated as an officer and an interim officer of Provectus Biopharmaceuticals, Inc. (the "Issuer"). This Form 4 serves as his exit filing. No acquisitions, dispositions or other transactions involving securities of the Issuer are being reported on this Form.